Mirae Asset Global Investments Co. Ltd. Acquires 10,319 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 25.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,170 shares of the company’s stock after acquiring an additional 10,319 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Roivant Sciences were worth $575,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. FMR LLC grew its position in Roivant Sciences by 8.1% during the 3rd quarter. FMR LLC now owns 38,910,625 shares of the company’s stock worth $454,476,000 after acquiring an additional 2,913,491 shares during the last quarter. Morgan Stanley grew its position in Roivant Sciences by 48.7% during the 3rd quarter. Morgan Stanley now owns 19,311,631 shares of the company’s stock worth $225,560,000 after acquiring an additional 6,324,915 shares during the last quarter. Rubric Capital Management LP lifted its holdings in Roivant Sciences by 196.9% during the 3rd quarter. Rubric Capital Management LP now owns 10,500,000 shares of the company’s stock worth $122,640,000 after buying an additional 6,963,562 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Roivant Sciences by 159.1% during the 3rd quarter. Vanguard Group Inc. now owns 5,602,566 shares of the company’s stock worth $65,438,000 after buying an additional 3,440,374 shares in the last quarter. Finally, Loomis Sayles & Co. L P lifted its holdings in Roivant Sciences by 1.2% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,984,935 shares of the company’s stock worth $23,184,000 after buying an additional 24,428 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Stock Down 0.2 %

NASDAQ:ROIV opened at $10.88 on Friday. Roivant Sciences Ltd. has a 12-month low of $8.06 and a 12-month high of $13.24. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $8.77 billion, a P/E ratio of 2.09 and a beta of 1.34. The stock’s fifty day simple moving average is $10.93 and its 200-day simple moving average is $10.36.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.07. The firm had revenue of $37.14 million for the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. Equities research analysts expect that Roivant Sciences Ltd. will post -1.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. TheStreet raised Roivant Sciences from a “d” rating to a “c+” rating in a report on Tuesday, February 13th. Deutsche Bank Aktiengesellschaft upped their price objective on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Truist Financial reaffirmed a “buy” rating and set a $23.00 price objective on shares of Roivant Sciences in a report on Monday, March 25th. Bank of America upped their price objective on Roivant Sciences from $11.00 to $12.00 and gave the stock a “neutral” rating in a report on Tuesday, January 2nd. Finally, Piper Sandler started coverage on Roivant Sciences in a report on Friday, January 5th. They set an “overweight” rating and a $20.00 price objective on the stock. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.90.

Insiders Place Their Bets

In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the transaction, the chief operating officer now directly owns 532,207 shares in the company, valued at $5,811,700.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.60% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.